Notable Tuesday Option Activity: MDGL, FIGR, CAPR

Figure Technology Solutions (FIGR) saw unusually high options activity with 14,853 contracts traded (≈1.5M underlying shares), about 63.1% of its one‑month average daily volume, led by 4,732 contracts in the $55 call expiring Feb 20, 2026 (≈473,200 shares). Capricor Therapeutics (CAPR) recorded 11,796 option contracts (≈1.2M shares), roughly 62.2% of its one‑month average daily volume, with heavy flow in the $25 put expiring Jan 16, 2026 (5,220 contracts, ≈522,000 shares). These concentrated option flows represent sizable positioning relative to each stock’s ADV and could presage directional pressure or hedging activity in the underlying equities.

Analysis

Market structure: Concentrated single‑strike flow (FIGR Feb20 2026 $55 calls ~4,732 contracts ≈473,200 shares; CAPR Jan16 2026 $25 puts ~5,220 contracts ≈522,000 shares) is large relative to each name’s ADV (FIGR ~63%, CAPR ~62%). That size suggests dealer hedging will create directional stock flow — delta-hedging buys into FIGR and sells/shorts CAPR — likely producing near-term price pressure in the same direction as the options. Impact is idiosyncratic to small-cap equity liquidity; negligible direct spillover to rates, FX, or commodities except through risk‑on/off microstructural moves in small-cap indices.

Risk assessment: Tail risks include misinterpretation of flow (blocks could be spreads/rolls), regulatory scrutiny for potential market manipulation, and sudden IV collapses; CAPR has biotech-specific binary risk (trial/FDA) that can move >50% intraday. Time horizons: immediate (days) dominated by dealer gamma hedging and increased intraday vol; short-term (weeks–months) by IV mean reversion and earnings/clinical catalysts; long-term (quarters+) fundamentals drive value. Hidden dependencies include concentration of market‑making counterparties and short interest; a large dealer hedge unwind could reverse direction quickly.

Trade implications: Prefer options-structured exposure over outright equity to control risk. For FIGR, asymmetric bullish trades (debit call spreads/long-dated calls sized 0.5–1% portfolio) capture upside while limiting theta. For CAPR, buy put spreads or hedge equity shorts (size 0.5–1.5%) to express bearish view; consider selling premium (calendar/iron condor) after IV spikes above 1.5x 30-day realized vol to harvest mean reversion.

Contrarian angles: The consensus that heavy call/put volume equals pure directional flow may be wrong — flows can be repositioning, covered call/collar writing, or arbitrage. Because implied vol likely climbed on the prints, selling premium on smaller notional (0.25–0.75% risk) could be alpha if no binary catalyst arrives within 60–90 days. Historical parallels: single-strike concentration in small-caps has produced short squeezes or snapback moves; manage liquidity risk and widen stops to account for widened spreads.

Key Decisions for Investors

• Establish a capped bullish position in FIGR: buy Feb 2026 $55/$65 call spread (or buy $55 call if spreads unavailable) sized to risk 1% of portfolio capital, enter within 7 trading days, take profit if FIGR > $65 (≈+2× premium) or cut loss if premium falls 60% or stock declines >20% from entry.
• Express bearish exposure to CAPR via a Jan16 2026 $25/$15 put spread sized to risk 1% of portfolio (max loss = premium), or short 1% notional equity with a hard stop at +15% adverse move; target >25% downside or IV-driven profit if put value doubles.
• If implied volatility for either ticker rises to >1.5× its 30‑day realized vol or option IV rank >70 within 10 trading days, sell short-dated premium (30–60 day iron condors or calendar spreads) in 0.25–0.75% risk increments to harvest mean reversion, avoid if imminent catalyst within 45 days.
• Monitor these specific triggers over next 30–90 days before scaling: FIGR filings/earnings dates, CAPR clinical/FDA milestones, changes in short interest >5 percentage points, or 13D/secondary offering filings; pause new positions 5 trading days ahead of confirmed binary events.